Bladder cancers rely upon TGFα as the primary EGFR ligand [86], suggesting that therapeutics utilizing TGFα as a targeting agent would be beneficial for treatment of these malignancies. The gene discussed is EGFR; the disease is urinary bladder carcinoma.